Concepts (120)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Pericarditis, Constrictive | 1 | 2017 | 21 | 0.71 | Why? |
| Pneumonia, Pneumococcal | 1 | 2020 | 251 | 0.68 | Why? |
| Pericardial Effusion | 1 | 2017 | 312 | 0.51 | Why? |
| Pleural Effusion | 1 | 2017 | 680 | 0.44 | Why? |
| Heart Injuries | 1 | 2017 | 608 | 0.41 | Why? |
| Hospital Mortality | 4 | 2020 | 22087 | 0.27 | Why? |
| Anti-Bacterial Agents | 3 | 2020 | 10083 | 0.25 | Why? |
| Heparin, Low-Molecular-Weight | 2 | 2020 | 1731 | 0.22 | Why? |
| Thyrotoxicosis | 1 | 2021 | 59 | 0.22 | Why? |
| Percutaneous Coronary Intervention | 1 | 2017 | 3646 | 0.21 | Why? |
| Coinfection | 1 | 2020 | 6820 | 0.21 | Why? |
| Levofloxacin | 1 | 2020 | 115 | 0.20 | Why? |
| Cobicistat | 1 | 2020 | 172 | 0.20 | Why? |
| Postoperative Complications | 1 | 2017 | 5861 | 0.18 | Why? |
| Chromosomes, Human, Pair 3 | 1 | 2020 | 195 | 0.18 | Why? |
| Ceftriaxone | 1 | 2020 | 365 | 0.18 | Why? |
| Antihypertensive Agents | 2 | 2020 | 1962 | 0.18 | Why? |
| Antigens, Bacterial | 1 | 2020 | 330 | 0.17 | Why? |
| Pericardiocentesis | 1 | 2017 | 84 | 0.17 | Why? |
| Darunavir | 1 | 2020 | 477 | 0.16 | Why? |
| Streptococcus pneumoniae | 1 | 2020 | 827 | 0.14 | Why? |
| Pulmonary Artery | 1 | 2020 | 803 | 0.13 | Why? |
| Noninvasive Ventilation | 2 | 2018 | 2329 | 0.13 | Why? |
| Prednisone | 1 | 2017 | 652 | 0.12 | Why? |
| Immunity, Herd | 1 | 2021 | 1011 | 0.12 | Why? |
| Respiratory Insufficiency | 3 | 2020 | 7301 | 0.12 | Why? |
| Syndrome | 1 | 2017 | 1310 | 0.12 | Why? |
| Ferritins | 1 | 2020 | 2055 | 0.11 | Why? |
| ABO Blood-Group System | 1 | 2020 | 995 | 0.11 | Why? |
| Drug Combinations | 1 | 2020 | 3852 | 0.11 | Why? |
| Pneumonia, Bacterial | 1 | 2017 | 843 | 0.10 | Why? |
| Lung Diseases, Interstitial | 1 | 2020 | 1476 | 0.09 | Why? |
| Anticoagulants | 2 | 2020 | 9563 | 0.09 | Why? |
| Idiopathic Pulmonary Fibrosis | 1 | 2014 | 595 | 0.09 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.08 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2020 | 3607 | 0.08 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.08 | Why? |
| Ritonavir | 1 | 2020 | 4212 | 0.07 | Why? |
| Azithromycin | 1 | 2020 | 3943 | 0.07 | Why? |
| Genetic Predisposition to Disease | 1 | 2020 | 4027 | 0.07 | Why? |
| Gastrointestinal Diseases | 1 | 2020 | 2580 | 0.07 | Why? |
| Community-Acquired Infections | 1 | 2017 | 2328 | 0.07 | Why? |
| Angiotensin Receptor Antagonists | 1 | 2020 | 3892 | 0.07 | Why? |
| Radiography, Thoracic | 1 | 2020 | 5486 | 0.06 | Why? |
| Echocardiography | 1 | 2017 | 3661 | 0.06 | Why? |
| Pneumonia, Viral | 6 | 2020 | 243684 | 0.06 | Why? |
| Heart Diseases | 1 | 2020 | 3503 | 0.06 | Why? |
| Coronavirus Infections | 6 | 2020 | 253789 | 0.06 | Why? |
| Length of Stay | 1 | 2020 | 11042 | 0.06 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 5277 | 0.06 | Why? |
| Aged | 10 | 2020 | 215776 | 0.06 | Why? |
| Olfaction Disorders | 1 | 2020 | 3704 | 0.06 | Why? |
| Italy | 6 | 2020 | 38444 | 0.05 | Why? |
| Disease Progression | 1 | 2020 | 13580 | 0.05 | Why? |
| Pneumonia | 2 | 2018 | 5652 | 0.05 | Why? |
| Middle Aged | 10 | 2021 | 270681 | 0.05 | Why? |
| Mass Screening | 1 | 2020 | 8005 | 0.05 | Why? |
| Chromosomes, Human, Pair 9 | 1 | 2020 | 196 | 0.05 | Why? |
| Hospitals | 1 | 2020 | 11793 | 0.05 | Why? |
| Thyrotropin | 1 | 2021 | 262 | 0.05 | Why? |
| Thyroxine | 1 | 2021 | 250 | 0.05 | Why? |
| Male | 11 | 2021 | 367725 | 0.05 | Why? |
| Multigene Family | 1 | 2020 | 377 | 0.05 | Why? |
| Female | 11 | 2021 | 380317 | 0.05 | Why? |
| Hypertension | 1 | 2020 | 8895 | 0.05 | Why? |
| Genetic Loci | 1 | 2020 | 439 | 0.05 | Why? |
| Hospitalization | 3 | 2020 | 54280 | 0.05 | Why? |
| Anti-Inflammatory Agents | 1 | 2017 | 6153 | 0.04 | Why? |
| Retrospective Studies | 5 | 2020 | 105322 | 0.04 | Why? |
| Aged, 80 and over | 4 | 2020 | 88759 | 0.04 | Why? |
| Humans | 17 | 2021 | 930598 | 0.04 | Why? |
| Treatment Outcome | 3 | 2020 | 51732 | 0.04 | Why? |
| Hypercapnia | 1 | 2018 | 172 | 0.04 | Why? |
| Tomography, X-Ray Computed | 2 | 2021 | 25144 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.04 | Why? |
| Emergency Service, Hospital | 2 | 2020 | 14232 | 0.04 | Why? |
| Vaccination | 1 | 2021 | 19050 | 0.04 | Why? |
| Predictive Value of Tests | 2 | 2020 | 9537 | 0.04 | Why? |
| Cryptogenic Organizing Pneumonia | 1 | 2014 | 35 | 0.04 | Why? |
| Protective Factors | 1 | 2020 | 1720 | 0.03 | Why? |
| Logistic Models | 2 | 2020 | 9089 | 0.03 | Why? |
| Partial Pressure | 1 | 2014 | 279 | 0.03 | Why? |
| Platelet Count | 1 | 2020 | 1381 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2020 | 2324 | 0.03 | Why? |
| Cross-Sectional Studies | 1 | 2020 | 53120 | 0.03 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.03 | Why? |
| Genome-Wide Association Study | 1 | 2020 | 1648 | 0.03 | Why? |
| Pandemics | 7 | 2021 | 389249 | 0.03 | Why? |
| Risk Assessment | 3 | 2021 | 25439 | 0.03 | Why? |
| Pulmonary Gas Exchange | 1 | 2014 | 414 | 0.03 | Why? |
| Smell | 1 | 2020 | 1851 | 0.03 | Why? |
| Prospective Studies | 3 | 2021 | 43301 | 0.03 | Why? |
| Autoantibodies | 1 | 2021 | 2094 | 0.02 | Why? |
| Continuous Positive Airway Pressure | 1 | 2018 | 1187 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2020 | 5440 | 0.02 | Why? |
| Survivors | 1 | 2021 | 2619 | 0.02 | Why? |
| Taste Disorders | 1 | 2020 | 1720 | 0.02 | Why? |
| Telemedicine | 1 | 2020 | 25032 | 0.02 | Why? |
| Adult | 3 | 2020 | 244371 | 0.02 | Why? |
| Precision Medicine | 1 | 2017 | 1477 | 0.02 | Why? |
| Radiography | 1 | 2014 | 1576 | 0.02 | Why? |
| Cause of Death | 1 | 2020 | 4823 | 0.02 | Why? |
| Time Factors | 2 | 2020 | 31397 | 0.02 | Why? |
| Comorbidity | 2 | 2020 | 34796 | 0.02 | Why? |
| Patient Admission | 1 | 2020 | 5250 | 0.02 | Why? |
| Time-to-Treatment | 1 | 2020 | 5883 | 0.02 | Why? |
| Mortality | 1 | 2020 | 7132 | 0.02 | Why? |
| Sex Factors | 1 | 2020 | 11014 | 0.02 | Why? |
| Acute Disease | 1 | 2014 | 6029 | 0.01 | Why? |
| Spain | 1 | 2020 | 15545 | 0.01 | Why? |
| Risk Factors | 2 | 2020 | 71621 | 0.01 | Why? |
| Case-Control Studies | 1 | 2020 | 17671 | 0.01 | Why? |
| Oxygen | 1 | 2014 | 3715 | 0.01 | Why? |
| Registries | 1 | 2020 | 12327 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2020 | 11041 | 0.01 | Why? |
| Age Factors | 1 | 2020 | 21039 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2017 | 17020 | 0.01 | Why? |
| Prevalence | 1 | 2020 | 25773 | 0.01 | Why? |
| Prognosis | 1 | 2020 | 32490 | 0.01 | Why? |
| Cohort Studies | 1 | 2020 | 36005 | 0.01 | Why? |
Voza's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(120)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(262)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_